Accesswire
13 Aug 2026, 11:50 UTC · 11w ago
Microbix Reports Results for Q3 Fiscal 2026
Impact · against what's priced in
Microbix is showing signs of a sequential recovery with 17% Q3 revenue growth and expanding gross margins, though the YTD picture remains bleak due to a $4 million loss in China sales. The strong liquidity position provides a buffer, but the stock's valuation depends on whether the Q3 trajectory can permanently offset the loss of large clients.
- MBX+0.10
No priced-in read yet
- In context
Q3 revenue grew 17% to $4.06 million and gross margins improved to 54%, signaling a recovery from 2025 setbacks, though YTD revenue remains down 21% due to a $4 million drop in China sales.
Read from the article alone
